Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Construction in Progress (2016 - 2017)

Northwest Biotherapeutics' Construction in Progress history spans 3 years, with the latest figure at $47.3 million for Q4 2017.

  • Quarterly results put Construction in Progress at $47.3 million for Q4 2017, up 6.19% from a year ago — trailing twelve months through Dec 2017 was $47.3 million (up 6.19% YoY), and the annual figure for FY2017 was $47.3 million, up 6.19%.
  • Construction in Progress for Q4 2017 was $47.3 million at Northwest Biotherapeutics, roughly flat from $47.3 million in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $47.3 million in Q3 2017 to a low of $44.6 million in Q4 2016.
  • The 3-year median for Construction in Progress is $46.0 million (2015), against an average of $46.0 million.
  • The sharpest move saw Construction in Progress dropped 2.46% in 2016, then rose 6.19% in 2017.
  • Year by year, Construction in Progress stood at $45.7 million in 2015, then fell by 2.46% to $44.6 million in 2016, then rose by 6.19% to $47.3 million in 2017.
  • According to Business Quant data, Construction in Progress over the past three periods came in at $47.3 million, $47.3 million, and $46.2 million for Q4 2017, Q3 2017, and Q2 2017 respectively.